Effect of Sugammadex vs Neostigmine on Postoperative Adverse Respiratory Events in Older Patients undergoing Lung Surgery

Effect of Sugammadex vs Neostigmine on Postoperative Adverse Respiratory Events in Older Patients undergoing Lung Surgery: a Prospective Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094005

Enrollment

Unknown

Registered

2024-12-16

Start date

2024-12-20

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Experimental Group:Sugammadex 2mg/kg was administered intravenously

Control group:Neostigmine 0.05mg/kg was administered intravenously

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Informed consent was obtained; 2.Age >= 65 years; 3.ASA grade <= III; 4.Selective thoracoscopic unilateral lung resection (including wedge, segmental, lobar); 5.Rocuronium was used for induction and maintenance of anesthesia;

Exclusion criteria

Exclusion criteria: 1.Participating in other interventional studies or refusing to sign informed consent; 2.Previous history of lung surgery; 3.COPD GOLD stage III and IV, Pulmonary fibrosis, pulmonary bullae, Severe emphysema, Pneumothorax (Pneumothorax at surgical side was not considered in this study); 4.Uncontrolled asthma; 5.Thoracotomy for pulmonary resection; 6.Tracheostomy; 7.Heart failure was classified as NYHA class 3 and 4, and coronary heart disease as CCS class 3 and 4; 8.Documented or suspected neuromuscular disease (thymoma, myasthenia, myopathy, muscular atrophy, and others); 9.Emergency surgery; 10.Allergic to either of the trial drugs; 11.Suffers from mental illness and cannot communicate normally; Or problems with language communication;

Design outcomes

Primary

Measure	Time frame
Adverse Respiratory Events;	—

Secondary

Measure	Time frame
Administer muscle relaxant antagonists until the time of tracheal extubation;Any adverse respiratory event in the PACU;Remedial measures for adverse respiratory events in PACU;Duration of Stay in the Recovery Room;Pulmonary complications within 7 days after surgery;Extra-pulmonary complications during hospitalization after surgery;Unplanned transfer from PACU to ICU;Time from completion of surgery to removal of thoracic drainage tube;Postoperative hospitalization days;In-hospital mortality rate;30 day mortality rate;	—

Measure

Time frame

Administer muscle relaxant antagonists until the time of tracheal extubation;Any adverse respiratory event in the PACU;Remedial measures for adverse respiratory events in PACU;Duration of Stay in the Recovery Room;Pulmonary complications within 7 days after surgery;Extra-pulmonary complications during hospitalization after surgery;Unplanned transfer from PACU to ICU;Time from completion of surgery to removal of thoracic drainage tube;Postoperative hospitalization days;In-hospital mortality rate;30 day mortality rate;

—

Countries

China

Contacts

Public ContactLyu Xin

Shanghai Pulmonary Hospital

xinlvg@126.com+86 13661869972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026